Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Demetri

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
American Journal of Hypertension|July 13, 2012
Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1Nilka de Jesus-Gonzalez, Emily Robinson, Radostin Penchev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamideJoseph R Mace, Mary L Keohan, Heinz Bernardy, et al.
European Journal of Cancer (Oxford, England : 1990)|January 4, 2020
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomasGregory M Cote, Edwin Choy, Tianqi Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumorsWilliam D Tap, George Demetri, Phillip Barnette, et al.
Cancer Research|October 30, 2010
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancersTakaaki Sasaki, Katsuhiro Okuda, Wei Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humansW Nicholas Haining, Jeffrey Davies, Holger Kanzler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatinGeoffrey D Girnun, Liang Chen, Jessica Silvaggi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2026
A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)Gregory M Cote, Mason Aberoumand, Edwin Choy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2008
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyEric Winer, Julie Gralow, Lisa Diller, et al.
Future Oncology (London, England)|February 11, 2025
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcomaGregory M Cote, Sant P Chawla, George Demetri, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
American Journal of Hypertension|July 13, 2012
Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1Nilka de Jesus-Gonzalez, Emily Robinson, Radostin Penchev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamideJoseph R Mace, Mary L Keohan, Heinz Bernardy, et al.
European Journal of Cancer (Oxford, England : 1990)|January 4, 2020
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomasGregory M Cote, Edwin Choy, Tianqi Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumorsWilliam D Tap, George Demetri, Phillip Barnette, et al.
Cancer Research|October 30, 2010
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancersTakaaki Sasaki, Katsuhiro Okuda, Wei Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humansW Nicholas Haining, Jeffrey Davies, Holger Kanzler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatinGeoffrey D Girnun, Liang Chen, Jessica Silvaggi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2026
A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)Gregory M Cote, Mason Aberoumand, Edwin Choy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2008
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyEric Winer, Julie Gralow, Lisa Diller, et al.
Future Oncology (London, England)|February 11, 2025
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcomaGregory M Cote, Sant P Chawla, George Demetri, et al.
Pageof 3